LAG3 and non-small cell lung carcinoma: Against this background, the study NEOpredict-Lung (NCT04205552) was designed to explore the feasibility and safety of preoperative dual targeting of PD-1 and LAG-3 in patients with resectable NSCLC stages IB, II or IIIA (Fig. 1a and Supplementary information).